A091902 (Soft Tissue Sarcoma)

What is the Purpose of this Study?

We are enrolling people who have not been treated with a class of anticancer drugs called taxanes.

If you join this study, you will:
- Be randomly assigned (a fair 50/50 chance) to either Group 1 or Group 2
-- Group 1 will get treatment with a chemotherapy drug called paclitaxel and the study drug nivolumab
-- Group 2 will get treatment with paclitaxel alone
What is the Condition Being Studied?
Soft Tissue Sarcoma (Angiosarcoma)

Who Can Participate in this Study?

Adults ages 18 and older who have angiosarcoma.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see how an experimental drug called nivolumab works in your body and against your cancer.

Study Details

Full Title
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Principal Investigator
Jeffrey Crawford
George Barth Geller Distinguished Professor for Research in Cancer

Contacts
Protocol Number
IRB:
PRO00107811

NCT:
NCT04339738
ClinicalTrials.gov
View on ClinicalTrials.gov